Out of Stock-5%Rx only
WILSONS PHARMACEUTICALS
A2A Tablets 50mg (1 Box = 2 Strips) (1 Strip = 10 Tablets)
1 Box(s) × 20 Units
Rated 0.0 out of 5 (0)
Rs. 621.40Rs. 654.20
Out of Stock
-5%Rx only
-5%Rx only
NOVARTIS PHARMACEUTICALS
Uperio Tablets 100mg (1 Strip = 14 Tablets)
Rated 0.0 out of 5 (0)SKU 1000000014201
Buy UPERIO 100 MG TABLETS from NOVARTIS PHARMACEUTICALS and get it delivered at your door step only from Dvago
Rs. 2,120.02Rs. 2,231.60-5%
You save Rs. 111.58
1 Strip(s) × 14 Tablets
Only 2 leftSet your city for an exact delivery date
In stock at selected branches
Prescription required
A licensed pharmacist will verify your prescription and call you within 15 minutes before this is dispensed.
Upload your prescriptionQuantity
Uperio Tablets 100mg (1 Strip = 14 Tablets) quantity: 1
- 100% authentic
- Free over Rs. 1,500
- Pharmacist verified
- 7-day returns
Total for 1 pack: Rs. 2,120.02
Sacubitril + valsartan inhibits neprilysin (neutral endopeptidase; NEP) , the active metabolite of the prodrug sacubitril and blocks the angiotensin II type-1 (AT1) receptor via valsartan. The cardiovascular and renal effects of sacubitril + valsartan in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides (NPs) and the simultaneous inhibition of the effects of angiotensin II by valsartan. NPs exert their effects by activating membrane bound guanylyl cyclase coupled receptors, resulting in increased concentrations of the second messenger cyclic guanosine monophosphate (cGMP), which could result in vasodilation, natriuresis and diuresis, increased glomerular filtration rate and renal blood flow, inhibition of renin and aldosterone release, reduction ofsympathetic activity and antihypertrophic and antifibrotic effects. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor and also inhibits angiotensin II-dependent aldosterone release. This prevents sustained activation of the renin-angiotensin-aldosterone system that would result in vasoconstriction, renal sodium and fluid retention, activation of cellular growth and proliferation and subsequent maladaptive cardiovascular remodeling.
Sacubitril + Valsartan is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. Sacubitril + Valsartan is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
- Heart Failure
The recommended starting dose of Sacubitril + Valsartan is one tablet of 49mg + 51mg twice daily.The dose of Sacubitril + Valsartan should be doubled after 2 to 4 weeks to the target maintenance dose of one tablet of 97mg + 103mg twice daily, as tolerated by the patient. Starting dose for some populations : A starting dose of (Sacubitril + Valsartan) one tablet of 24mg + 26mg taken twice daily is recommended for patients not currently taking an ACE inhibitor or an ARB or patients previously taking low doses of these agents. A starting dose of Sacubitril + Valsartan of one tablet of 24mg + 26mg taken twice daily should be considered for patients who have risk factors for hypotension, including patients = 75 years old and patients with low systolic blood pressure (SBP =100 to 110 mmHg). The dose of Sacubitril + Valsartan should be doubled every 2-4 weeks to the target dose of one tablet of Sacubitril + Valsartan 97mg + 103 mg twice daily, as tolerated by the patient. Always consult your doctor or pharmacist for dose adjustments.
Follow your doctor’s instructions. The dosage above is the usual range — your prescription takes precedence over it.
Sacubitril , Valsartan
- Sacubitril + valsartan lowers blood pressure and may cause symptomatic hypotension. Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. Correct volume or salt depletion prior to administration of sacubitril + valsartan or start at a lower dose. If hypotension occurs, consider dose adjustment of diuretics, concomitant antihypertensive drugs and treatment of other causes of hypotension (e.g., hypovolemia). If hypotension persists despite such measures, reduce the dosage or temporarily discontinue sacubitril + valsartan.
- Through its actions on the RAAS, hyperkalemia may occur with sacubitril + valsartan. Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism or a high potassium diet. Dosage reduction or interruption of sacubitril + valsartan may be required.
- Caution should be exercised when initiating sacubitril + valsartan in patients with NYHA functional classification IV due to limited clinical experience in this population.
Store this medicine at room temperature, away from direct light and heat.
Manufactured by NOVARTIS PHARMACEUTICALS. Country of origin: Pakistan.
0.0
Rated 0.0 out of 50 verified ratings
- 5★0%
- 4★0%
- 3★17%
- 2★0%
- 1★0%
- Zainab H.Verified Purchase4 Aug 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument. Prescription was verified by phone before dispatch, which built confidence.
- Ayesha K.Verified Purchase20 Jul 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Mehwish A.Verified Purchase19 Jul 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Usman TariqVerified Purchase26 Jun 2026Rated 3.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Rabia N.Verified Purchase25 Jun 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Kamran AliVerified Purchase26 May 2026Rated 0.0 out of 5
Fine quality, wrong choice on my part — I should have asked the pharmacist first about the strength.
Reviews are from verified Hope Pharmacy orders. We do not remove a review for being critical.
Sacubitril + valsartan inhibits neprilysin (neutral endopeptidase; NEP) , the active metabolite of the prodrug sacubitril and blocks the angiotensin II type-1 (AT1) receptor via valsartan. The cardiovascular and renal effects of sacubitril + valsartan in heart failure patients are attributed to the increased levels of peptides that are degraded by neprilysin, such as natriuretic peptides (NPs) and the simultaneous inhibition of the effects of angiotensin II by valsartan. NPs exert their effects by activating membrane bound guanylyl cyclase coupled receptors, resulting in increased concentrations of the second messenger cyclic guanosine monophosphate (cGMP), which could result in vasodilation, natriuresis and diuresis, increased glomerular filtration rate and renal blood flow, inhibition of renin and aldosterone release, reduction ofsympathetic activity and antihypertrophic and antifibrotic effects. Valsartan inhibits the effects of angiotensin II by selectively blocking the AT1 receptor and also inhibits angiotensin II-dependent aldosterone release. This prevents sustained activation of the renin-angiotensin-aldosterone system that would result in vasoconstriction, renal sodium and fluid retention, activation of cellular growth and proliferation and subsequent maladaptive cardiovascular remodeling.
Sacubitril + Valsartan is indicated in adult patients for treatment of symptomatic chronic heart failure with reduced ejection fraction. Sacubitril + Valsartan is usually administered in conjunction with other heart failure therapies, in place of an ACE inhibitor or other ARB.
- Heart Failure
The recommended starting dose of Sacubitril + Valsartan is one tablet of 49mg + 51mg twice daily.The dose of Sacubitril + Valsartan should be doubled after 2 to 4 weeks to the target maintenance dose of one tablet of 97mg + 103mg twice daily, as tolerated by the patient. Starting dose for some populations : A starting dose of (Sacubitril + Valsartan) one tablet of 24mg + 26mg taken twice daily is recommended for patients not currently taking an ACE inhibitor or an ARB or patients previously taking low doses of these agents. A starting dose of Sacubitril + Valsartan of one tablet of 24mg + 26mg taken twice daily should be considered for patients who have risk factors for hypotension, including patients = 75 years old and patients with low systolic blood pressure (SBP =100 to 110 mmHg). The dose of Sacubitril + Valsartan should be doubled every 2-4 weeks to the target dose of one tablet of Sacubitril + Valsartan 97mg + 103 mg twice daily, as tolerated by the patient. Always consult your doctor or pharmacist for dose adjustments.
Follow your doctor’s instructions. The dosage above is the usual range — your prescription takes precedence over it.
Sacubitril , Valsartan
- Sacubitril + valsartan lowers blood pressure and may cause symptomatic hypotension. Patients with an activated renin-angiotensin system, such as volume- and/or salt-depleted patients (e.g., those being treated with high doses of diuretics), are at greater risk. Correct volume or salt depletion prior to administration of sacubitril + valsartan or start at a lower dose. If hypotension occurs, consider dose adjustment of diuretics, concomitant antihypertensive drugs and treatment of other causes of hypotension (e.g., hypovolemia). If hypotension persists despite such measures, reduce the dosage or temporarily discontinue sacubitril + valsartan.
- Through its actions on the RAAS, hyperkalemia may occur with sacubitril + valsartan. Monitor serum potassium periodically and treat appropriately, especially in patients with risk factors for hyperkalemia such as severe renal impairment, diabetes, hypoaldosteronism or a high potassium diet. Dosage reduction or interruption of sacubitril + valsartan may be required.
- Caution should be exercised when initiating sacubitril + valsartan in patients with NYHA functional classification IV due to limited clinical experience in this population.
Store this medicine at room temperature, away from direct light and heat.
Manufactured by NOVARTIS PHARMACEUTICALS. Country of origin: Pakistan.
0.0
Rated 0.0 out of 50 verified ratings
- 5★0%
- 4★0%
- 3★17%
- 2★0%
- 1★0%
- Zainab H.Verified Purchase4 Aug 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument. Prescription was verified by phone before dispatch, which built confidence.
- Ayesha K.Verified Purchase20 Jul 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Mehwish A.Verified Purchase19 Jul 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Usman TariqVerified Purchase26 Jun 2026Rated 3.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Rabia N.Verified Purchase25 Jun 2026Rated 0.0 out of 5
The product is genuine but did not suit me personally. Customer service handled the return without any argument.
- Kamran AliVerified Purchase26 May 2026Rated 0.0 out of 5
Fine quality, wrong choice on my part — I should have asked the pharmacist first about the strength.
Reviews are from verified Hope Pharmacy orders. We do not remove a review for being critical.
Frequently bought together
- NOVARTIS PHARMACEUTICALSUperio Tablets 100mg (1 Strip = 14 Tablets)Rs. 2,120.02Rated 0.0 out of 5
ESSA LAB25-Hydroxy Vitamin D TestRs. 3,460Rated 0.0 out of 5
SANTE (PRIVATE) LIMITED2Blink Eye Drops 15mlRs. 500.56Rated 0.0 out of 5
Bundle total
Rs. 6,080.58Rs. 6,218.51
Information on this site is for general guidance and is not a substitute for professional medical advice. Always consult your doctor or pharmacist.
You might also like
More in this range
Out of Stock
